{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:31:34Z","timestamp":1777563094506,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703014"],"award-info":[{"award-number":["81703014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Municipal Science and Technology Program","doi-asserted-by":"publisher","award":["20YDTPJC00950"],"award-info":[{"award-number":["20YDTPJC00950"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.bcp.2024.116077","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:51:49Z","timestamp":1708516309000},"page":"116077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis"],"prefix":"10.1016","volume":"222","author":[{"given":"Guoyang","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Futao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cen","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herve","family":"Galons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuou","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116077_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10549-023-06958-4","article-title":"Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34","volume":"200","author":"Altwegg","year":"2023","journal-title":"Breast Cancer Res Tr"},{"key":"10.1016\/j.bcp.2024.116077_b0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA-Cancer J Clin"},{"key":"10.1016\/j.bcp.2024.116077_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.730442","article-title":"Identification of Immune-Related Risk Characteristics and Prognostic Value of Immunophenotyping in TNBC","volume":"12","author":"Yi","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.bcp.2024.116077_b0020","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/1535-7163.MCT-15-0519","article-title":"Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer","volume":"15","author":"Jabbour-Leung","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bcp.2024.116077_b0025","doi-asserted-by":"crossref","unstructured":"Peter, M, Fischer, Athos, Gianella-Borradori. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. EXPERT OPIN INV DRUG 2005.","DOI":"10.1517\/13543784.14.4.457"},{"key":"10.1016\/j.bcp.2024.116077_b0030","doi-asserted-by":"crossref","unstructured":"Zhao P, Song H, Gao F, Chen L, Qiu J, Jin J, et al. A Novel Derivative of Curcumol, HCL-23, Inhibits the Malignant Phenotype of Triple-Negative Breast Cancer and Induces Apoptosis and HO-1-Dependent Ferroptosis. MOLECULES 2023;28.","DOI":"10.3390\/molecules28083389"},{"key":"10.1016\/j.bcp.2024.116077_b0035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-dependent transcriptional addiction in triple-negative breast cancer","volume":"163","author":"Wang","year":"2015","journal-title":"CELL"},{"key":"10.1016\/j.bcp.2024.116077_b0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2013.07.012","article-title":"A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis","volume":"24","author":"Kollmann","year":"2013","journal-title":"CANCER CELL"},{"key":"10.1016\/j.bcp.2024.116077_b0045","doi-asserted-by":"crossref","unstructured":"Syed YY. Sacituzumab Govitecan: First Approval. DRUGS 2020;80:1019-25.","DOI":"10.1007\/s40265-020-01337-5"},{"key":"10.1016\/j.bcp.2024.116077_b0050","doi-asserted-by":"crossref","unstructured":"Weiss J, Glode A, Messersmith WA, Diamond JR. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. EXPERT REV ANTICANC 2019;19.","DOI":"10.1080\/14737140.2019.1654378"},{"key":"10.1016\/j.bcp.2024.116077_b0055","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14712598.2017.1331214","article-title":"Sacituzumab govitecan: an antibody-drug conjugate","volume":"17","author":"Sahota","year":"2017","journal-title":"Expert Opin Biol Th"},{"key":"10.1016\/j.bcp.2024.116077_b0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cdd.2011.96","article-title":"Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012","volume":"19","author":"Galluzzi","year":"2012","journal-title":"Cell Death & Differentiation"},{"key":"10.1016\/j.bcp.2024.116077_b0065","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbrc.2018.12.087","article-title":"Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells","volume":"508","author":"Wen","year":"2019","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.bcp.2024.116077_b0070","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2017.10.006","article-title":"Mitochondria, bioenergetics and apoptosis in cancer","volume":"3","author":"Burke","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bcp.2024.116077_b0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.fct.2016.04.020","article-title":"Pomegranate peel extract polyphenols induced apoptosis in human hepatoma cells by mitochondrial pathway","volume":"93","author":"Song","year":"2016","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.bcp.2024.116077_b0080","doi-asserted-by":"crossref","unstructured":"Hengartner MO. The biochemistry of apoptosis. NATURE 2000;407:770-6.","DOI":"10.1038\/35037710"},{"key":"10.1016\/j.bcp.2024.116077_b0085","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2147\/DDDT.S282913","article-title":"Caspase cascade activation during apoptotic cell death of human lung carcinoma cells a549 induced by marine sponge callyspongia aerizusa","volume":"15","author":"Hadisaputri","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bcp.2024.116077_b0090","doi-asserted-by":"crossref","unstructured":"Estaphan S, Malek RA, Rashed L, Mohamed EA. Cimetidine a promising radio\u2010protective agent through modulating Bax\/Bcl2 ratio: An in vivo study in male rats. J CELL PHYSIOL 2020;235.","DOI":"10.1002\/jcp.29692"},{"key":"10.1016\/j.bcp.2024.116077_b0095","doi-asserted-by":"crossref","unstructured":"Stein Y, Rotter V, Aloni-Grinstein R. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis. INT J MOL SCI 2019;20.","DOI":"10.3390\/ijms20246197"},{"key":"10.1016\/j.bcp.2024.116077_b0100","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","article-title":"Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer","volume":"26","author":"Roberts","year":"2007","journal-title":"ONCOGENE"},{"key":"10.1016\/j.bcp.2024.116077_b0105","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bcp.2024.116077_b0110","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1111\/jcmm.17529","article-title":"Ferroptosis in tumor immunity and therapy","volume":"26","author":"Gong","year":"2022","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bcp.2024.116077_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.597434","article-title":"Role of GPX4-mediated ferroptosis in the sensitivity of triple negative breast cancer cells to gefitinib","volume":"10","author":"Song","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.bcp.2024.116077_b0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s12951-021-01058-1","article-title":"Simvastatin induced ferroptosis for triple-negative breast cancer therapy","volume":"19","author":"Yao","year":"2021","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.bcp.2024.116077_b0125","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41467-021-20904-2","article-title":"NUPR1 is a critical repressor of ferroptosis","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2024.116077_b0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27452-9","article-title":"A targetable LIFR\u2212NF-\u03baB\u2212LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis","author":"Yao","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bcp.2024.116077_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120704","article-title":"CRISPR\/Cas9-mediated knockout of Lcn2 in human breast cancer cell line MDA-MB-231 ameliorates erastin-mediated ferroptosis and increases cisplatin vulnerability","volume":"304","author":"Valashedi","year":"2022","journal-title":"Life Sci"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:38:27Z","timestamp":1777401507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"alternative-id":["S0006295224000601"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116077","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116077"}}